CORNEAL AND OCULAR SURFACE IMMUNOLOGY AND REGENERATION
Associate Professor Holly Chinnery,
Inaugural Ian Constable Research Fellow,
Lions Eye Institute,
UWA Optometry at The University of Western Australia
RESEARCHER PROFILE
Filmed in Perth, Western Australia | November 2024
Associate Professor Holly Chinnery is a teaching and research academic in the field of corneal and ocular immunology who has spent her career teaching anatomy and immunology to Optometry students at the University of Melbourne and now at UWA, while also leading a Corneal and Ocular Immunology Research team.
Career highlights include:
– Leading a team of students and early career staff over the past 15 years working on corneal and retinal immunology, a co-leading the FrontTear Research Centre with Professor Laura Downie at the University of Melbourne https://www.fronttear.au/
– Receiving NH&MRC Ideas and ARC Discovery Grant funding
– Speaking invitations at Oxford University, University of Birmingham and the Association for Research in Vision and Ophthalmology; and recent publications in PNAS and Nature Reviews Immunology.
Assoc Professor Chinnery’s career in ocular immunology began with a focus on animal models; however, it has recently transitioned into clinical imaging studies involving human research participants. The ability to visualise the immune system and sensory nerves in the human cornea represents a significant advantage in corneal immunology and neuroimmunology research.
This advancement is made possible through a methodology called Functional In Vivo Confocal Microscopy (Fun-IVCM), which enables the observation of immune cell dynamics in the living human eye. Utilising this technology led to a breakthrough in the field of ocular immunology, culminating in a report published in PNAS, a highly prestigious journal, regarding the presence of T cells in the healthy human cornea https://www.pnas.org/doi/full/10.1073/pnas.2217795120.
This finding challenges existing dogmas and is poised to reshape the field of corneal immunology, prompting a reconsideration of previously held beliefs about how the cornea manages inflammation and immune protection, with direct implications for healthy vision.
For the first time, a variety of immune cells can be visualised in the living human cornea, generating a wealth of new questions about immunology, cell biology, and the effects that diseases outside the eye have on immune cells at the eye’s surface.
In her recent appointment at the Lions Eye Institute, Assoc Professor Chinnery aims to establish and support a team of researchers focused on corneal and ocular surface regeneration, which is one of the key research priorities of the Institute.
You Might also like
-
Superslayer taking on antibiotic-resistant bacteria
Dr Katharina Richter is a visionary leader in MedTech, acclaimed for innovation and gender diversity. With over 40 awards to her name, including MIT Innovator Under 35 Asia-Pacific, and Prime Minister’s Prize for New Innovator finalist, she has shattered barriers as an entrepreneur, scientist, and ‘superbug slayer.’ Katharina’s groundbreaking work in combating antibiotic-resistant bacteria has resulted in 6 innovative treatments, 3 of which are patented, offering hope against deadly infections.
-
Understanding the experience of pain for novel brain-based treatments
Associate Professor Tasha Stanton leads the Persistent Pain Research Group at SAHMRI. She is also co-Director of IIMPACT in Health at the University of South Australia, Adelaide. She is a clinical pain neuroscientist, with original training as a physiotherapist, and her research focusses on pain – why do we have it and why doesn’t it go away?
-
Targeting chemotherapy resistance in ovarian cancer patients
Dr Alex Cole, from the Centenary Institute’s Centre for Biomedical AI, is now leading the research focused on developing a new treatment to counteract a protein called follistatin (FST), known for making ovarian cancer cells resistant to chemotherapy.
By employing cutting-edge molecular biology and directed evolution techniques, the project aims to create nanobodies—small, precise molecules—that can block FST. If successful, these nanobodies could enhance the effectiveness of chemotherapy and improve ovarian cancer treatment rates.